Pharmacoeconomic evaluation of the MF59 - Adjuvanted influenza vaccine in the elderly population in Italy

Journal of Preventive Medicine and Hygiene

Volumn 52, Issue 1, 2011, Pages 1-8

  Iannazzo, Sergio ^a  

^a AdRes Health Economics and Outcomes Research   (Italy)

Author keywords

Adjuvanted vaccine; Budget impact analysis; Influenza vaccination

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; COST CONTROL; DEATH; DEMOGRAPHY; FINANCIAL MANAGEMENT; HEALTH CARE PLANNING; HEALTH ECONOMICS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INFLUENZA; INFORMATION RETRIEVAL; ITALY; MAJOR CLINICAL STUDY; NONHUMAN; PHARMACOECONOMICS; PUBLISHING; RESIDENT; SIMULATION;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; COSTS AND COST ANALYSIS; DISEASE OUTBREAKS; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ITALY; MALE; MODELS, ECONOMIC; POLYSORBATES; SEASONS; SQUALENE;

EID: 79958774857     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80.
2. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177-84.
3. Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008;26:1525-9.
4. Mauskopf J, Sullivan S, Annemans L, et al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value Health 2007;10:336-47.
5. ISTAT - Italian National Institute of Statistics. Resident Population at 1st January 2010. www.demo.istat.it/pop2010/index
6. ISTAT - Italian National Institute of Statistics. Health, risk factors and use of health services - data 2005 (Condizioni di salute, fattori di rischio e ricorso ai servizi sanitari). http://www.istat.it/salastampa/comunicati/non- calendario/20070302-00/ Last accessed February 2010.
7. Italian Ministry of Health. Influenza vaccination: season 2009-2010 (Vaccinazione antinfluenzale: stagione 2009-2010). Available online at http://www.salute.gov.it/influenza/paginaInternaMenuInfluenza.jsp?id= 679&menu=strumentieservizi. Last accessed Jan 2011.
8. Bocchino B, Bove E, Bonomo G, et al. Impact of the influenza vaccination in the healthcare service local unit of Benevento (Impatto della Vaccinazione Antinfluenzale nella ASL di Benevento). EpiCentro Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute. Available online at http://www.epicentro.iss.it/focus/influenza/flu-benev.asp. Last accessed February 2010.
9. Montomoli E, Pozzi T, Alfonsi V. Cost-benefit assessment of the influenza vaccination in the elderly: two epidemic seasons in comparison in the province of Siena (Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in due stagioni epidemiche a confronte nella provincia di Siena). Pharmacoeconomics Italian Research Articles 2003;5(Suppl 1):31-8.
10. Gasparini R, Lucioni C, Lai P. Cost-benefit assessment of the influenza vaccination in the elderly in the Liguria region (valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in Liguria). Italian Research Articles 2003;5(Suppl 1):23-30.
11. Scuffham P, West P. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002;20:2562-78.
12. Piercy J, Ryan J, Megas F. Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France. J Med Econ 2004;7:1-18.
13. Baio G, Pammolli F, Baldo V, Trivello R et al. Object-oriented influence diagram for cost-effectiveness analysis of influenza vaccination in the Italian elderly population. Expert Rev Pharmacoecon Outcomes Res 2006;6:293-301.
14. Ryan J, Zoellner Y, Gradl B, et al. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006;24:6812-22
15. Puig-Barberà J, Díez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007;25:7313-21.
16. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006;3:CD004876.
17. th International Congress on Infectious Diseases. 2004, Cancun, Mexico.
18. Mannino S, Villa M, Weiss N, et al. Effectiveness of influenza vaccination with Fluad versus a sub-unit influenza vaccine. Am J Epidemiol 2010;171(Suppl):S1-157
19. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-65.
20. Pontrelli G, Bella A, Salmaso S. Survey on the organizational aspects of the seasonal influenza vaccination campaign (Indagine sugli aspetti organizzativi della campagna stagionale di vaccinazione antinfluenzale). Bollettino Epidemiologico Nazionale - Notiziario ISS 2004;17.
21. Garattini L, Castelnuovo E, Lanzeni D, et al. Time and cost of visits in general practice: the DYSCO project (Durata e costo delle visite in medicina generale: il progetto DYSCO). Farmeconomia e Percorsi Terapeutici 2003;4:109-14.
22. Gazzetta Ufficiale n. 134 del 12-6-2006. Intesa, ai sensi dell'articolo 2 della legge 26 maggio 2004, n. 138, di conversione in legge del decreto-legge 29 marzo 2004, n. 81. Supplemento Ordinario alla Gazzetta Ufficiale n.143. Provvedimento 23 marzo 2005 (Italian Official Journal (Gazzetta Ufficiale) Law n. 134 June 12, 2006.).
23. ISTAT - Italian National Institute of Statistics. Price index for currency revaluations. December 2009. Available at http://www.istat.it/prezzi/ precon/rivalutazioni/ Last accessed February 2010.
24. Sessa A, Bettoncelli G, D'Ambrosio G, et al. Study 606: the influence observed through X-rays (Lo studio 606: l'influenza ai raggi X). Rivista SIMG 2002, n. 2
25. Aballéa S, Chancellor J, Martin M, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 2007;10:98-116
26. L'Informatore Farmaceutico. Italian directory of medicines and manufacturers. 69th Rev. Milano: Elsevier 2009
27. Nomenclatore Tariffario Nazionale: DRG tariffs. DMS 2006 Sep 12. Supplemento Ordinario alla Gazzetta Ufficiale 2006 Dec 13;289
28. Ministry of Health - Hospital Discharge Records database: Available online at http://www.ministerosalute.it/programmazione/sdo/ric-informazioni/ default.jsp
29. Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008;26:1525-9.
30. Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Eujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24:3063-5.
31. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010;2010:517198.